SCHEMBL792992

SCHEMBL792992

Cc1cc(-c2ccc(Br)cc2)n[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 1.00
SMN1; SMN2 Q16637 2/20 1.00
RAB9A P51151 1/20 1.00
L3MBTL1 Q9Y468 1/20 0.66
CYP1A2 P05177 1/20 0.54
CYP2D6 P10635 1/20 0.54
CYP19A1 P11511 1/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54
ALK Q9UM73 1/20 0.51
IKBKB O14920 1/20 0.49
CHUK O15111 1/20 0.49
METAP2 P50579 1/20 0.46
CCNA2 P20248 1/20 0.45
CDK2 P24941 1/20 0.45
CCNA1 P78396 1/20 0.45
KDM4E B2RXH2 2/20 0.44
PDE10A Q9Y233 1/20 0.44
GAA P10253 1/20 0.44
HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2766145 0.83 RAB9A (0.71) NPC1SMN1; SMN2RAB9AL3MBTL1CYP1A2
SCHEMBL27741318 0.83 NPC1 (0.70) NPC1SMN1; SMN2RAB9AL3MBTL1CYP1A2
SCHEMBL1160360 0.80 NPC1 (0.67) NPC1SMN1; SMN2RAB9AL3MBTL1CYP1A2
SCHEMBL15908507 0.80 NPC1 (0.67) NPC1SMN1; SMN2RAB9AL3MBTL1CYP1A2
SCHEMBL14097585 0.80 L3MBTL1 (0.92) NPC1SMN1; SMN2RAB9AL3MBTL1CYP1A2
SCHEMBL2360295 0.80 NPC1 (0.67) NPC1SMN1; SMN2RAB9AL3MBTL1CYP1A2
SCHEMBL16115554 0.79 NPC1 (0.66) NPC1SMN1; SMN2RAB9AL3MBTL1ALK
SCHEMBL21198241 0.79 SMN1; SMN2 (0.66) NPC1SMN1; SMN2RAB9AL3MBTL1CYP1A2
SCHEMBL427627 0.79 L3MBTL1 (1.00) NPC1SMN1; SMN2RAB9AL3MBTL1CYP1A2
SCHEMBL13363876 0.78 CYP1A2 (0.66) NPC1SMN1; SMN2RAB9AL3MBTL1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113354635-B Pyrrolidine integrin regulator and application thereof 清药同创(北京)药物研发中心有限公司 2023-04-18 CN disclosed
EP-3950678-A1 AROMATIC AMINE COMPOUND AND USE THEREOF IN PREPARATION OF AR AND BRD4 DUAL INHIBITORS AND REGULATORS Hinova Pharmaceuticals Inc. (CN) 2022-02-09 EP disclosed
CN-113354635-A Pyrrolidine integrin regulator and application thereof 清药同创(北京)药物研发中心有限公司 2021-09-07 CN disclosed
CN-111793031-B Aromatic amine compound and application thereof in preparation of AR and BRD4 dual inhibitor and regulator 海创药业股份有限公司 2021-06-22 CN disclosed
CN-111793031-A Aromatic amine compound and application thereof in preparation of AR and BRD4 dual inhibitor and regulator 成都海创药业有限公司 2020-10-20 CN disclosed
WO-2020200209-A1 AROMATIC AMINE COMPOUND AND USE THEREOF IN PREPARATION OF AR AND BRD4 DUAL INHIBITORS AND REGULATORS 成都海创药业有限公司 2020-10-08 WO disclosed
EP-2225211-B1 HERBICIDAL PYRIDAZINONE DERIVATIVES DU PONT (US) 2013-10-02 EP disclosed
EP-2616443-A1 PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS Exelixis, Inc. (US) 2013-07-24 EP disclosed
US-20130165440-A1 JAK1 Inhibitors EXELIXIS, INC. (US) 2013-06-27 US disclosed
US-20130165440-A1 JAK1 Inhibitors EXELIXIS, INC. (US) 2013-06-27 US disclosed
US-20120095044-A1 TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION Sanford-Burnham Medical Research Institute California 2012-04-19 US disclosed
WO-2012037132-A1 PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS EXELIXIS, INC. (US) 2012-03-22 WO disclosed
WO-2012037132-A1 PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS EXELIXIS, INC. (US) 2012-03-22 WO disclosed
US-8119693-B2 Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2012-02-21 US disclosed
US-20100267561-A1 HERBICIDAL PYRIDAZINONE DERIVATIVES E. I. DU PONT DE NEMOURS AND COMPANY 2010-10-21 US disclosed
EP-2225211-A1 HERBICIDAL PYRIDAZINONE DERIVATIVES E. I. du Pont de Nemours and Company (US) 2010-09-08 EP disclosed
WO-2010046780-A2 ANTI VIRAL COMPOUNDS INSTITUT PASTEUR KOREA (KR) 2010-04-29 WO disclosed
WO-2009086041-A1 HERBICIDAL PYRIDAZINONE DERIVATIVES E. I. DU PONT DE NEMOURS AND COMPANY (US) 2009-07-09 WO disclosed
US-20090156560-A1 TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE 2009-06-18 US disclosed
WO-2009017863-A2 TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2009-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095044-A1 TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION ALPL, CNDP2, ALPI NPC1 2886/4885SMN1; SMN2 4792/4885RAB9A 3655/4885
US-20090156560-A1 TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION ALPL, CNDP2, ALPI NPC1 2886/4885SMN1; SMN2 4792/4885RAB9A 3655/4885
US-20130165440-A1 JAK1 Inhibitors JAK1, JAK2, JAK3 NPC1 2912/4885SMN1; SMN2 3265/4885RAB9A 1911/4885
US-20100267561-A1 HERBICIDAL PYRIDAZINONE DERIVATIVES CYP1A1, CYP1B1, CBR3 NPC1 4290/4885SMN1; SMN2 4277/4885RAB9A 3035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.